Cargando…

Survival Rates of Patients with Non-Small Cell Lung Cancer Depending on Lymph Node Metastasis: A Focus on Saliva

The aim of this study was to compare overall survival (OS) rates at different pN stages of NSCLC depending on tumor characteristics and to assess the applicability of saliva biochemical markers as prognostic signs. The study included 239 patients with NSCLC (pN(0)-120, pN(1)-51, pN(2)-68). Saliva wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Bel’skaya, Lyudmila V., Sarf, Elena A., Kosenok, Victor K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8161301/
https://www.ncbi.nlm.nih.gov/pubmed/34065406
http://dx.doi.org/10.3390/diagnostics11050912
_version_ 1783700478148739072
author Bel’skaya, Lyudmila V.
Sarf, Elena A.
Kosenok, Victor K.
author_facet Bel’skaya, Lyudmila V.
Sarf, Elena A.
Kosenok, Victor K.
author_sort Bel’skaya, Lyudmila V.
collection PubMed
description The aim of this study was to compare overall survival (OS) rates at different pN stages of NSCLC depending on tumor characteristics and to assess the applicability of saliva biochemical markers as prognostic signs. The study included 239 patients with NSCLC (pN(0)-120, pN(1)-51, pN(2)-68). Saliva was analyzed for 34 biochemical indicators before the start of treatment. For pN(0), the tumor size does not have a prognostic effect, but the histological type should be taken into account. For pN(1) and pN(2), long-term results are significantly worse in squamous cell cancer with a large tumor size. A larger volume of surgical treatment reduces the differences between OS. The statistically significant factors of an unfavorable prognosis at pN(0) are the lactate dehydrogenase activity <1294 U/L and the level of diene conjugates >3.97 c.u. (HR = 3.48, 95% CI 1.21–9.85, p = 0.01541); at pN(1), the content of imidazole compounds >0.296 mmol/L (HR = 6.75, 95% CI 1.28–34.57, p = 0.00822); at pN(2) levels of protein <0.583 g/L and Schiff bases >0.602 c.u., as well as protein >0.583 g/L and Schiff bases <0.602 c.u. (HR = 2.07, 95% CI 1.47–8.93, p = 0.04351). Using salivary biochemical indicators, it is possible to carry out stratification into prognostic groups depending on the lymph node metastasis.
format Online
Article
Text
id pubmed-8161301
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81613012021-05-29 Survival Rates of Patients with Non-Small Cell Lung Cancer Depending on Lymph Node Metastasis: A Focus on Saliva Bel’skaya, Lyudmila V. Sarf, Elena A. Kosenok, Victor K. Diagnostics (Basel) Article The aim of this study was to compare overall survival (OS) rates at different pN stages of NSCLC depending on tumor characteristics and to assess the applicability of saliva biochemical markers as prognostic signs. The study included 239 patients with NSCLC (pN(0)-120, pN(1)-51, pN(2)-68). Saliva was analyzed for 34 biochemical indicators before the start of treatment. For pN(0), the tumor size does not have a prognostic effect, but the histological type should be taken into account. For pN(1) and pN(2), long-term results are significantly worse in squamous cell cancer with a large tumor size. A larger volume of surgical treatment reduces the differences between OS. The statistically significant factors of an unfavorable prognosis at pN(0) are the lactate dehydrogenase activity <1294 U/L and the level of diene conjugates >3.97 c.u. (HR = 3.48, 95% CI 1.21–9.85, p = 0.01541); at pN(1), the content of imidazole compounds >0.296 mmol/L (HR = 6.75, 95% CI 1.28–34.57, p = 0.00822); at pN(2) levels of protein <0.583 g/L and Schiff bases >0.602 c.u., as well as protein >0.583 g/L and Schiff bases <0.602 c.u. (HR = 2.07, 95% CI 1.47–8.93, p = 0.04351). Using salivary biochemical indicators, it is possible to carry out stratification into prognostic groups depending on the lymph node metastasis. MDPI 2021-05-20 /pmc/articles/PMC8161301/ /pubmed/34065406 http://dx.doi.org/10.3390/diagnostics11050912 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Bel’skaya, Lyudmila V.
Sarf, Elena A.
Kosenok, Victor K.
Survival Rates of Patients with Non-Small Cell Lung Cancer Depending on Lymph Node Metastasis: A Focus on Saliva
title Survival Rates of Patients with Non-Small Cell Lung Cancer Depending on Lymph Node Metastasis: A Focus on Saliva
title_full Survival Rates of Patients with Non-Small Cell Lung Cancer Depending on Lymph Node Metastasis: A Focus on Saliva
title_fullStr Survival Rates of Patients with Non-Small Cell Lung Cancer Depending on Lymph Node Metastasis: A Focus on Saliva
title_full_unstemmed Survival Rates of Patients with Non-Small Cell Lung Cancer Depending on Lymph Node Metastasis: A Focus on Saliva
title_short Survival Rates of Patients with Non-Small Cell Lung Cancer Depending on Lymph Node Metastasis: A Focus on Saliva
title_sort survival rates of patients with non-small cell lung cancer depending on lymph node metastasis: a focus on saliva
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8161301/
https://www.ncbi.nlm.nih.gov/pubmed/34065406
http://dx.doi.org/10.3390/diagnostics11050912
work_keys_str_mv AT belskayalyudmilav survivalratesofpatientswithnonsmallcelllungcancerdependingonlymphnodemetastasisafocusonsaliva
AT sarfelenaa survivalratesofpatientswithnonsmallcelllungcancerdependingonlymphnodemetastasisafocusonsaliva
AT kosenokvictork survivalratesofpatientswithnonsmallcelllungcancerdependingonlymphnodemetastasisafocusonsaliva